Delivery Order SPE2DR25D1053-SPE2DR26FT180
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $91,743.02 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $4,184.06 under firm fixed price terms. The order is scheduled for completion by September 10, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $17,061.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is scheduled for completion by September 26, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $10,591.02. This is a firm fixed price delivery order with no set-aside designation, awarded competitively to the prime contractor. The order is to be completed by August 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a...
- The Defense Logistics Agency awarded a $30,588.59 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a competitively awarded, non-set-aside procurement issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is listed as AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $73,823.96 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $13,293.08. This firm fixed-price delivery order, which is effective through August 27, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT180Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors, with a contract ceiling value of $3,603.02 and an ultimate completion date of October 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate headquarters and distribution facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger SPE2DX Indefinite Delivery Contract, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, reflecting the breadth of pharmaceutical products supplied by AmerisourceBergen through its federal contracts to support military and veteran healthcare needs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 10/22/25 |